- Johnson & Johnson (NYSE:JNJ) is beginning the process of seeking a buyer for its Cordis unit that makes medical devices including stents and catheters, WSJ reports.
- Cordis reportedly could fetch $1.5B-$2B and is expected to attract interest from P-E firms and other health care companies.
- A sale would mark the latest divestiture for JNJ, which is looking to shed slower-growth businesses and reduce annual costs by $1B; JNJ said in 2011 it would leave the cardiac stent business after years of falling sales and market share.
From other sites
Video at CNBC.com (Jul 20, 2015)
Video at CNBC.com (Jul 14, 2015)
Video at CNBC.com (May 27, 2015)
at CNBC.com (May 22, 2015)
Video at CNBC.com (May 20, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs